Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Atirmociclib by Pfizer for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Atirmociclib is under clinical development by Pfizer and currently in Phase III for Human Epidermal Growth Factor Receptor 2 Negative...
Atirmociclib by Pfizer for Metastatic Breast Cancer: Likelihood of Approval
Atirmociclib is under clinical development by Pfizer and currently in Phase III for Metastatic Breast Cancer. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Pfizer's Atirmociclib?
Atirmociclib is a small molecule commercialized by Pfizer, with a leading Phase III program in Metastatic Breast Cancer;Human Epidermal Growth...